BRAF and colorectal carcinoma: The detection of BRAF oncogenic mutation was the first step to determine the proportion of patients that may benefit from BRAF inhibitors targeted therapy to start the correct treatment, to shed light on the most effective regimens, to decrease the costs and the side effects caused by maltreating wild-type melanoma and CRC by BRAF inhibitors, and to improve the quality of life, decrease mortality, and increase the overall survival of patients. It is important to follow up with the patients concerning the therapy, outcomes, and its clinicopathological measures.